COMMUNIQUÉS West-GlobeNewswire

Transactions in relation to share buyback program
05/02/2019
Acting under its share buyback authorization, the GN Store Nord Board of Directors initiated a share buyback program on May 2, 2018, in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]
LIDDS adds another Scandinavian clinic to the NZ-DTX-001 clinical trial
05/02/2019
UPPSALA, SWEDEN - LIDDS AB (publ) has received approval from the Danish Medicines Agency (DKMA) to conduct its Phase I NZ-DTX-001 clinical trial. The Danish study is in addition to the Phase I NZ-DTX-001 clinical trial [...]
Novo Nordisk files annual report with the SEC
05/02/2019
Bagsværd, Denmark, 5 February 2019 - Novo Nordisk A/S has filed its Annual Report 2018 on Form 20-F for the financial year 2018 with the US Securities and Exchange Commission (SEC), incorporating by reference parts of [...]
CellaVision AB launches new product, CellaVision® DC-1, for small and mid-sized hematology laboratories
05/02/2019
The information was released for public disclosure on February 5, 2019, at 08:20. The CellaVision® DC-1 strengthens the company's global position and opens a new segment of the market comprising about 100,000 small and [...]
Ossur Hf : Annual Report 2018
05/02/2019
Announcement no. 8/2019 Annual Report 2018 5 February 2019 Össur's Annual Report 2018 has just been published and is available for download at the link below. Online version of the Annual Report 2018 is available at [...]
Ossur Hf : Interim report Q4 2018
05/02/2019
Announcement no. 7/2019 Interim report Q4 2018 5 February 2019 Highlights Sales growth of 12% in local currency in Q4 2018, organic sales growth of 4% and reported growth of 9%. Sales growth of 7% in local currency in [...]
Annual Report 2018 for H.Lundbeck A/S
05/02/2019
Annual Report 2018 for H.Lundbeck A/S Attachment ANNUALREPORT2018
Lundbeck realized 8% growth in revenue (local currencies) and 48% growth in EPS in 2018
05/02/2019
Financial report for the period 1 January to 31 December 2018 Lundbeck realized 8% growth in revenue (local currencies) and 48% growth in EPS in 2018 HIGHLIGHTS Revenue reached DKK 18,117 million in 2018 representing an [...]
Neovacs to host KOL Meeting to discuss its therapeutic vaccin IFNalpha Kinoid for lupus treatment - February 11th Paris
05/02/2019
NEOVACS TO HOST KOL MEETING TO DISCUSS ITS THERAPEUTIC VACCINE IFN α KINOID FOR LUPUS TREATMENT FEBRUARY 11, 2019 – 17h00 Hôtel Renaissance Le Parc Trocadéro – Paris Paris and Boston, February 5 th 2019 – 7h30 CET - [...]
Néovacs organise une réunion KOL concernant son vaccin thérapeutique IFNalpha Kinoïde pour le traitement du lupus - 11 février à Paris
05/02/2019
NÉOVACS ORGANISE UNE RÉUNION KOL CONCERNANT SON VACCIN THÉRAPEUTIQUE IFNα KINOÏDE POUR LE TRAITEMENT DU LUPUS 11 FÉVRIER 2019 – 17h00 Hôtel Renaissance Le Parc Trocadéro - Paris Paris et Boston, le 5 février 2019 – 7h30 [...]
Sanofi : Isatuximab Phase 3 trial meets primary endpoint of prolonging progression free survival in patients with relapsed/refractory multiple myeloma
05/02/2019
Isatuximab Phase 3 trial meets primary endpoint of prolonging progression free survival in patients with relapsed/refractory multiple myeloma Study evaluated the benefit of isatuximab in combination with standard of [...]
Sanofi : L'essai de phase III consacré à l'isatuximab a atteint son critère d'évaluation principal de prolongation de la survie sans progression chez des patients atteints d'un myélome multiple ré...
05/02/2019
L'essai de phase III consacré à l'isatuximab a atteint son critère d'évaluation principal de prolongation de la survie sans progression chez des patients atteints d'un myélome multiple récidivant/réfractaire L'essai a [...]
Idorsia announces the first patient recruited into REACT - the Phase 3 registration study with clazosentan
05/02/2019
REACT assesses the efficacy and safety of intravenous clazosentan for the prevention of clinical deterioration due to vasospasm-related delayed cerebral ischemia following aneurysmal subarachnoid hemorrhage (aSAH) On [...]
GENFIT: Reports Full-Year 2018 Financial Results: cash position of €207.2m as of 12.31.2018
05/02/2019
GENFIT: Reports Full-Year 2018 Financial Results: cash position of €207.2m as of 12.31.2018 GENFIT achieved significant development milestones in 2018: Completed enrollment of interim analysis cohort for phase 3 RESOLVE [...]
GENFIT : Résultats financiers 2018 : Trésorerie de clôture de 207.2m€ au 31.12.2018
05/02/2019
GENFIT : Résultats financiers 2018 : Trésorerie de clôture de 207.2m€ au 31.12.2018 Étapes décisives franchies par GENFIT en 2018 : achèvement du recrutement de la cohorte d'analyse intermédiaire de l'essai de phase 3 [...]
Veritas Pharma to Proceed with Share Consolidation
05/02/2019
VANCOUVER, British Columbia, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) announces that it is proceeding with a consolidation of its [...]
The Ensign Group Schedules Year-End 2018 Earnings Call for Thursday, February 7, 2019
05/02/2019
MISSION VIEJO, Calif., Feb. 04, 2019 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of skilled nursing, rehabilitative care services, assisted living, home health, [...]
REVA Announces Reduction in Force
05/02/2019
SAN DIEGO, Feb. 04, 2019 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, announced it is realigning the organization [...]
PRA Health Sciences to Report Fourth Quarter 2018 Earnings
04/02/2019
RALEIGH, N.C., Feb. 04, 2019 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its fourth quarter and year end 2018 results after the market closes on Wednesday, February 27, 2019. The Company [...]

Pages